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Cancer has been linked to HIV since the earliest days of the
epidemic. The unusually frequent occurrence of Kaposi sarcoma (KS)
among men who have sex with men (MSM) in 1981 was a sentinel
observation leading to the inclusion of KS in the first AIDS case
definition.1,2 More than three decades later, major research invest-
ments have led to striking advances in understanding HIV pathogen-
esis, with antiretroviral therapy (ART) reducing AIDS complications
and allowing HIV-infected individuals to experience life expectancy
approaching that of persons without HIV.3,4
HIV confers an increased risk for many cancers.5-9 Although
ART has reduced incidence of certain cancers like KS and non-
Hodgkin lymphoma (NHL), risks for these cancers are still in-
creased.5,8,10 With reduced mortality from AIDS in the ART era,
HIV-infected people are also aging, leading to a growing cancer bur-
den.11 As a result, cancer has become a leading cause of HIV-
associated death in resource-rich settings, and the leading cause in
several HIV cohorts.12-15 Many uncertainties remain about the under-
lying pathogenesis of cancer, as well as optimal prevention and treat-
ment strategies in HIV-infected populations. Because HIV-infected
individuals on effective ART are increasingly unlikely to die of AIDS,
tailored cancer prevention and treatment are needed to maximize life
expectancy gains.
Against this background, there is an opportunity to develop a
modern, global agenda for HIV-associated cancer which is well suited
to the current era. We believe such an agenda requires epidemiologic
research that is biologically informed, greater molecular insights to
guide treatment, optimized cancer screening and prevention strat-
egies, and inclusion of HIV-infected populations from resource-
limited settings.
Biologically Informed Epidemiologic Research
Malignancies associated with HIV have been historically dichot-
omized as AIDS-defining cancers (ADCs) or non–AIDS-defining
cancers (NADCs), according to the 1993 Centers for Disease Control
(CDC) definition.16 This dichotomy groups together KS, certain NHL
subtypes, and cervical cancer as ADCs, while classifying all other
cancers as NADCs despite clear epidemiologic and biologic links to
HIV in many instances. More recently, malignancies in HIV-infected
people have been categorized as infection-related or infection-
unrelated.7 Grouping cancers in these ways can increase the number of
cancers under evaluation in research studies.
However, when substantial etiologic heterogeneity exists within
cancer groups defined for analytic purposes, these groupings can
obscure rather than facilitate pathogenic and clinical insights. Table 1,
which lists several cancers for which risk is increased in the context of
HIV, demonstrates that similarities and differences between cancers
often cut across conventional classification schemes. Although the
ADC/NADC and infection-related/infection-unrelated distinctions
have questionable relevance, they remain in widespread use, and
many HIV cohorts continue to collect data solely on ADCs.
To demonstrate, cervical cancer is an ADC, and anal cancer is an
NADC. However, among HIV-infected people in the United States,
excess risk is greater for anal cancer than for cervical cancer.5-8,17,27
This pattern may, in part, be a result of a high proportion of MSM in
the US HIV-infected population,28 as well as successful cervical cancer
screening among HIV-infected women.29 Both cancers progress
through defined precursor lesions and are almost always caused by
human papillomavirus (HPV).18,19 Both cancers are preventable by
screening and vaccination and are treated similarly with surgery
and/or chemoradiotherapy. In this instance, the ADC/NADC distinc-
tion obscures the close kinship of these two cancers. Similarly, assign-
ment of NHL and Hodgkin lymphoma to different categories by using
the ADC/NADC scheme may be problematic, ignoring similarities
across these lymphomas with respect to Epstein-Barr virus (EBV),
which is etiologically implicated in a large portion of cases in HIV-
infected people.20-23 These shortcomings highlight the fact that the
1993 AIDS case definition was developed as a surveillance tool to track
the epidemic and that the ADC/NADC distinction has major limita-
tions as a cancer classification scheme.
Grouping cancers as infection-related or infection-unrelated is
another strategy in epidemiologic research. However, for some can-
cers, only subsets of cases are caused by infection. Classifying cancers
such as NHL or head and neck squamous cell carcinoma (HNSCC) as
infection-related, without pathologic or molecular identification of
oncogenic viruses in tumor specimens (EBV for NHL, HPV for
HNSCC), invariably misclassifies many virus-negative tumors.20,24,25
EBV is present in only 40% to 60% of NHL specimens, although there
is marked variation across histologic subtypes.20,21 For HNSCC, in-
creased rates of oral HPV acquisition or persistence may contribute to
the two- to three-fold increase in HNSCC associated with HIV,5-8,17
although the relative contribution of HPV versus tobacco and alcohol
use remains largely unknown in the HIV-infected population.
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Moreover, different oncogenic viruses cause cancer by different
mechanisms. Some viruses (eg, EBV for NHL) cause cancer by directly
transforming infected cells. In contrast, chronic hepatitis B and C
infections are associated with increased risk of NHL through indi-
rect mechanisms that likely involve chronic immune activation
and B-cell stimulation.30-32 Although EBV plays an important role
in NHL occurrence among HIV-infected individuals, hepatitis B
and C infections do not appear to contribute.33,34 Grouping to-
gether infections or infection-related cancers may therefore lead to
uninformative results in epidemiologic studies and obscure rele-
vant biologic mechanisms.
Molecular Insights to Guide Treatment
Cancer research has entered a molecular age, and characterizing
tumors with respect to causation by oncogenic viruses, as well as
immunophenotypic and genomic features, is increasingly important
to optimize treatment. For example, treatment de-escalation is under
active investigation in HPV-associated HNSCC, given the overall bet-
ter prognosis for these tumors.35,36 Likewise, sorafenib may be a more
effective treatment for hepatocellular carcinoma caused by hepatitis C
than hepatitis B for reasons that have not been fully elucidated.37-39
Different treatment approaches may soon be considered for diffuse
large B-cell lymphoma subtypes defined by gene expression profil-
ing,40,41 although clinical trials for HIV-associated lymphoma have
often enrolled patients with diffuse large B-cell lymphoma or Burkitt
lymphoma together and treated them as a single clinical entity.
Genomic characterizations have been infrequently applied to HIV-
infected patients for whom tumor biology may differ from that of
noninfected patients.42-45 Tumor biology also may differ within HIV-
infected populations on the basis of when cancer occurs along the
clinical course of HIV infection, given complex interactions between
ART use, HIV replication, immune suppression, aging, and other risk
factors that are dynamic over time.
Given the rarity of HIV-associated cancer in resource-rich set-
tings, no single center will have enough cases to study individual
cancers, especially molecularly defined subtypes. However, more
granular characterizations of tumors in HIV-infected patients can be
undertaken by pooling records and specimens from existing HIV
consortia. Such studies may be small and have limited power but can
provide opportunities to explore molecular cancer subtypes in detail
among HIV-infected persons. Research on HIV-associated cancers
can also be better integrated into the larger cancer research agenda,
with extrapolation when appropriate from studies in noninfected
patients. In the modern ART era, it should also be possible to include
HIV-infected patients as a subgroup in large collaborative studies,46 as
is now being done for Hodgkin lymphoma.47
Examples of these efforts are ongoing in the Centers for AIDS
Research (CFAR) Network of Integrated Clinical Systems (CNICS)
and cooperative clinical trial groups supported by the National Cancer
Institute (NCI), such as the AIDS Malignancy Consortium (AMC).48
In CNICS, a standardized data collection process for cancer has been
implemented that allows for a growing body of research that addresses
HIV-associated cancer.49-52 CNICS has also launched efforts to pool
specimens to perform translational studies of HPV in HIV-associated
HNSCCs and molecular profiling of lymphomas before and af-
ter ART.
Optimized Cancer Screening and Prevention
In HIV clinical settings, cancer screening is typically based on
guidelines developed for the general population, like those endorsed
by the United States Preventive Services Task Force (USPSTF). With
normalizing life expectancy, this may be appropriate for cancers for
which risk is similar between HIV-infected and HIV-uninfected peo-
ple, such as breast and prostate cancer. However, for other cancers,
performance of screening interventions may be sufficiently different
in HIV-infected individuals to warrant modified approaches.
For instance, cervical cancer screening intervals may need to be
shorter in HIV-infected women because of more frequent acquisition
of and persistence of oncogenic HPV subtypes and higher risk of
progression for precancerous lesions.53,54 Likewise, performance of
low-dose computed tomography (LDCT) for lung cancer screening
may be different in HIV-infected smokers who have high rates of lung
cancer but are also more likely to have LDCT-detected radiographic
abnormalities that require additional diagnostic work-up.55,56
In addition, cancer screening interventions without evidence of
benefit in the general population may be of value in HIV-infected
individuals because of different cancer risk profiles. One example is
screening for anal cancer, which has been widely adopted in HIV
clinics to reduce the high rates of anal cancer observed especially
among HIV-infected MSM. Current adoption is largely based on
extrapolation from cervical cancer screening, and rigorous evaluation
specifically for anal cancer screening is ongoing.55 In addition, the
optimal application of cancer screening in HIV-infected individuals
might vary with time on ART, since risk for various cancers is not
uniformly distributed over time.51
Vaccine strategies are also generally similar between HIV-
infected and HIV-uninfected populations, as in current recommen-
dations for HPV vaccination among children and young adults.
However, potential differences in HPV subtypes, age at acquisition,
and vaccine responsiveness may call for more nuanced guidelines
specifically for HIV-infected individuals.57 These issues may be
particularly salient in resource-limited settings in which introduc-
tion of HPV vaccine has only recently begun in many countries,
and where scarce resources call for cost-efficient vaccine programs
with optimal targeting of at-risk populations. Cancers caused by
EBV and Kaposi’s sarcoma-associated herpesvirus may eventually
also be preventable with vaccines, with early candidate vaccines for
EBV showing promise.58,59
Inclusion of HIV-Infected Populations From
Resource-Limited Settings
The paucity of research related to HIV-associated cancer in sub-
Saharan Africa provides a strong incentive to extend modern cancer
care and research to settings where resources are severely constrained
to learn lessons that are applicable at a global level.60 Of 34 million
HIV-infected individuals worldwide, 24 million (69%) reside in sub-
Saharan Africa.61 There is now the possibility of developing HIV-
associated cancer research programs in countries where large numbers
of patients can provide data that are informative to both resource-
limited and resource-rich settings. Such collaborations can provide a
platform for studying HIV-associated cancers that occur frequently in
many parts of Africa (eg, conjunctival squamous cell carcinoma) but
rarely in other parts of the world. Cancer control among HIV-infected
people in sub-Saharan Africa is handicapped by a high prevalence of
oncogenic viruses,62 advanced HIV illness before ART initiation, and
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limited ART availability, although remarkable progress has been made
and many countries now surpass the United States in ART coverage
rates.61 Such progress has led to an HIV epidemic in evolution, which
increasingly resembles resource-rich settings with high burdens of
chronic disease and cancer in aging HIV-infected populations. Cancer
screening is scarce in sub-Saharan Africa, although the HIV epidemic
has been a major impetus for introducing cervical cancer screen-
ing.63,64 Ongoing African studies of the AMC and the International
Epidemiologic Databases to Evaluate AIDS (IeDEA) consortium rep-
resent a promising foundation on which to build robust cancer re-
search collaborations in this part of the world.
In conclusion, a global, forward-looking agenda for HIV-
associated cancer should now be possible just as it has been for HIV,
and modern frameworks should replace outdated ones. The ADC/
NADC distinction predates the modern ART era and has little scien-
tific relevance. This construct should be abandoned in epidemiologic
research addressing HIV-associated cancers. Instead, research efforts
should be focused on individual cancers or, when necessary for ana-
lytic purposes, grouping cancers into categories that are informed by
underlying biologic mechanisms. In clinical treatment studies, molec-
ular tools should be used to identify clinically relevant patient subsets,
as is routinely done for HIV-uninfected patients. Optimizing cancer
screening and prevention strategies for HIV-infected populations is
equally important. Finally, extending care and research for HIV-
associated malignancies to parts of the world most affected by these
diseases can lead to important scientific and humanitarian advances.
Together, these efforts will allow patients to fully reap the benefits of
modern ART wherever they may live.
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